



## Pharmacy and Therapeutics Committee Meeting Agenda

---

**Wednesday, April 8, 2026**

7:30 – 9:30 am

To arrange for public building access, please contact  
Luke Nelson at 415-615-4269

San Francisco Health Plan  
50 Beale St.  
San Francisco, CA, 94105  
City Hall Conference Room

---

- 1) Call to order – non-voting item (est. time 5 minutes)  
*Steve O'Brien, MD, Chief Medical Officer, San Francisco Health Plan*
  - Attendance/Quorum
  - Agenda overview
  
- 2) Review and Approval of January 21, 2026, P&T minutes – **voting item** (est. time 3 minutes)  
*Steve O'Brien, MD, Chief Medical Officer, San Francisco Health Plan*
  
- 3) Informational Updates – non-voting item (est. time 10 minutes)  
*Steve O'Brien, MD, Chief Medical Officer, San Francisco Health Plan*  
*Brian Ellsworth, PharmD, Pharmacy Director, San Francisco Health Plan*
  - D-SNP updates
  - Healthy Workers HMO/Healthy San Francisco updates
  
- 4) Pharmacy Policies and Procedures (P&Ps) Review – **voting item** (est. time 10 minutes)  
*Sue Chan, Pharmacy Compliance Program Manager, San Francisco Health Plan*
  - Pharm-01 Pharmacy and Therapeutics Committee
  - Pharm-02 Pharmacy Prior Authorization
  - Pharm-07 Emergency Med Supply
  - Pharm-08 Annual Review (Retirement)
  - Pharm-11 Member Reimbursement for Pharmacy Services
  - Pharm-13 After-Hours Pharmacy Access
  - Pharm-14 Pharmacy Drug Utilization Review (DUR) Program
  - Pharm-15 Generic Drug Management (Retirement)
  - Pharm-16 Pharmacy System User Access
  
- ADJOURN TO CLOSED SESSION**  
*Steve O'Brien, MD, Chief Medical Officer, San Francisco Health Plan*
  
- 5) Interim Changes – non-voting item (est. time 10 minutes)  
*Eileen Kim, PharmD, Clinical Pharmacist, San Francisco Health Plan*  
*Ankur Kotecha, PharmD, Clinical Account Executive, MedImpact*
  - Formulary changes
  - Utilization management changes



## Pharmacy and Therapeutics Committee Meeting Agenda

- 6) Discussion and Recommendations for Changes to SFHP Formulary and Prior Authorization Criteria and Drug Utilization Review Reports for Select Drug Classes – non-voting item (est. time 40 mins)

*Eileen Kim, PharmD, Clinical Pharmacist, San Francisco Health Plan*

*Ankur Kotecha, PharmD, Clinical Account Executive, MedImpact*

- Neurology
  - Alzheimer’s Disease Class Review
- Neurology
  - Migraines Class Review
- Cardiology
  - Lerochol® (lerodalcibep) Monograph
- Pulmonology
  - Rhapsido® (remibrutinib) Monograph

- 7) DUR Program Updates, Reports, and/or Educational Items – non-voting item (est. time 15 minutes)

*Katie Vo, PharmD, Clinical Pharmacist, San Francisco Health Plan*

*Thy Pham, PharmD, Clinical Pharmacist, San Francisco Health Plan*

- Prime Rx Retrospective DUR Quarterly Activities 4Q2025
- Opioids and Narcan DUR Report Updates
- Proportion of Days Covered (PDC) Adherence Report
  - Hypertension
  - Hyperlipidemia
  - Diabetes

- 8) DSNP Stars Presentation – non-voting item (est. time 15 minutes)

*Katie Vo, PharmD, Clinical Pharmacist, San Francisco Health Plan*

- 9) Appendix: MedImpact Pipeline Report– non-voting item (est. time 10 minutes)

*Ankur Kotecha, PharmD, Clinical Account Executive, MedImpact*

### **RECONVENE IN OPEN SESSION**

Summary of Closed Session – non-voting item (est. time 2 minutes)

*Steve O’Brien, MD, Chief Medical Officer, San Francisco Health Plan*

- 10) Adjournment

- Upcoming P&T Committee meeting dates
  - **Wednesday, July 15, 2026**
  - **Wednesday, October 21, 2026**
  - **Wednesday, January 20, 2027**
  - **Wednesday, April 21, 2027**